Rohde D, De Mulder P H, Weissbach L, Osieka R, Blatter J, Jakse G
Department of Urology, Technical University of Aachen, Germany.
Oncology. 1996 Nov-Dec;53(6):476-81. doi: 10.1159/000227623.
Preclinical and clinical studies have been performed to evaluate the efficacy of gemcitabine (2',2'-difluorodeoxycytidine; dFdC) in human renal cell carcinoma. Experimental data corroborated dFdC as an effective drug against cell lines from renal cell carcinomas (ACHN, A-498, SN12C) at concentrations much below clinically achievable doses. ACHN-bearing nude mice showed an overall response rate of 27% to dFdC (3 mice with complete response, 1 with partial response, 3 with stable and 8 with progressive disease). Objective response from 37 evaluable patients was 8.1% (1 patient with complete response and 2 patients with partial response). Gemcitabine was well tolerated thus, although gemcitabine at the dosage and schedule chosen had only small activity, the observed toxicity may permit further dose escalation or a more frequent administration of the drug.
已经开展了临床前和临床研究，以评估吉西他滨（2'，2'-二氟脱氧胞苷；dFdC）对人肾细胞癌的疗效。实验数据证实，在远低于临床可达到剂量的浓度下，dFdC是一种针对肾细胞癌细胞系（ACHN、A-498、SN12C）的有效药物。携带ACHN的裸鼠对dFdC的总体反应率为27%（3只完全缓解、1只部分缓解、3只病情稳定、8只病情进展）。37例可评估患者的客观缓解率为8.1%（1例完全缓解、2例部分缓解）。吉西他滨耐受性良好，因此，尽管所选择的剂量和给药方案下的吉西他滨活性较小，但观察到的毒性可能允许进一步提高剂量或更频繁地给药。
